CoChat

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans

Open access

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of NAFLD, is associated with a loss of insulin sensitivity, it is not clear which cellular abnormality arises first. We have explored this in mice overexpressing carbohydrate responsive element-binding protein (ChREBP). On a standard diet, mice overexpressing ChREBP remained insulin sensitive, despite increased expression of genes involved in lipogenesis/fatty acid esterification and resultant hepatic steatosis (simple fatty liver). Lipidomic analysis revealed that the steatosis was associated with increased accumulation of monounsaturated fatty acids (MUFAs). In primary cultures of mouse hepatocytes, ChREBP overexpression induced expression of stearoyl-CoA desaturase 1 (Scd1), the enzyme responsible for the conversion of saturated fatty acids (SFAs) into MUFAs. SFA impairment of insulin-responsive Akt phosphorylation was therefore rescued by the elevation of Scd1 levels upon ChREBP overexpression, whereas pharmacological or shRNA-mediated reduction of Scd1 activity decreased the beneficial effect of ChREBP on Akt phosphorylation. Importantly, ChREBP-overexpressing mice fed a high-fat diet showed normal insulin levels and improved insulin signaling and glucose tolerance compared with controls, despite having greater hepatic steatosis. Finally, ChREBP expression in liver biopsies from patients with nonalcoholic steatohepatitis was increased when steatosis was greater than 50% and decreased in the presence of severe insulin resistance. Together, these results demonstrate that increased ChREBP can dissociate hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci41636

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Research works printed but not linked: 4

  1. Denechaud, 2008, J Clin Invest., 118, 956
  2. Kohjima, 2007, Int J Mol Med., 20, 351
  3. Semple, 2009, J Clin Invest., 119, 315
  4. 10.2337/db06-0200 · DOI · Paper page

Cited by

See all 408

Metadata

Authors
Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C.
Affiliations
  • Inserm (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Saint-Antoine (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Pitié-Salpêtrière Hospital (FR)
  • Toxicologie Alimentaire (FR)
  • Institut Cochin (FR)
Corresponding author
Postic, Catherine
Venue
Journal of Clinical Investigation
Published
2012-06-01
Volume
122
Issue
6
Pages
2176-2194
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2117220292
Cited by
408
References
94
Citations by year
2026: 15 · 2025: 24 · 2024: 22 · 2023: 35 · 2022: 27 · 2021: 28 · 2020: 34 · 2019: 23 · 2018: 25 · 2017: 35 · 2016: 27 · 2015: 30 · 2014: 41 · 2013: 27 · 2012: 13
FWCI
26.58
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion)
Funders
  • European Commission
  • Agence Nationale de la Recherche
  • Institut National de la Santé et de la Recherche Médicale (U1016)
  • Association Française pour l'Etude du Foie (AFEF-2008)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
ChREBP, carbohydrate-responsive element-binding protein, hepatic steatosis, insulin resistance, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipogenesis, fatty acid esterification, stearoyl-CoA desaturase 1, monounsaturated fatty acids, Akt phosphorylation, insulin signaling, glucose tolerance, high-fat diet, lipidomics, hepatocytes
MeSH terms
Animals, Fatty Acids, Monounsaturated, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Nuclear Proteins, Phosphorylation, Stearoyl-CoA Desaturase, Transcription Factors, Metabolic Syndrome, Lipogenesis, Proto-Oncogene Proteins c-akt, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. https://app.cochat.ai/papers/10.1172/jci41636
The paper
Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C. (2012). The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. Journal of Clinical Investigation. https://doi.org/10.1172/jci41636

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.